| Southeastern Healthcare Of Jacksonville | |
|
260 Memorial Dr, Jacksonville, NC 28546-6332 | |
| (910) 355-6000 | |
| (910) 355-7533 |
| Full Name | Southeastern Healthcare Of Jacksonville |
|---|---|
| Type | Facility |
| Speciality | Family Medicine |
| Location | 260 Memorial Dr, Jacksonville, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376505156 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Southeastern Healthcare Of Jacksonville 260 Memorial Dr, Jacksonville, NC 28546-6332 Ph: (910) 355-6000 | Southeastern Healthcare Of Jacksonville 260 Memorial Dr, Jacksonville, NC 28546-6332 Ph: (910) 355-6000 |
News Archive
A new grant to improve the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) will see NPS MedicineWise and consortium partners support specialist prescribers and help consumers get the most benefit from these complex medicines.
A new study by Israeli researchers tested the hypothesis that certain SARS-CoV-2 variants of concern can overcome protection conferred by Pfizer-BioNTech (BNT162b2) mRNA vaccine and found evidence of increased breakthrough rates in vaccinated individuals. The research paper is currently available on the medRxiv preprint server.
VeriChip Corporation ("VeriChip") (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled "Methods of Making Arrays and Artificial Receptors" and Patent No. 7,469,076 "Sensors Employing Combinatorial Artificial Receptors," in their application to the development of the virus triage detection system for the H1N1 virus.
Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth.
› Verified 1 days ago